Moderate riskFDA DrugClass II

Regeneron Libtayo injection recalled for lack of sterility assurance

Regeneron is recalling one lot of Libtayo (cemiplimab-rwlc), an intravenous cancer treatment, because the manufacturer cannot guarantee the vials are sterile. This affects lot 8494000002, which expires July 31, 2028. About 21,353 vials are involved in the recall nationwide.

From the FDA notice · Read the official notice ↗

What to do

  1. Contact your healthcare provider or hospital if you received Libtayo from this lot
  2. Do not use vials from lot 8494000002 if you have them in storage
  3. Ask your provider about obtaining unaffected product or alternative treatment

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Libtayo (cemiplimab-rwlc) Injection, 350 mg/7 mL (50 mg/mL), For Intravenous Infusion After Dilution, Single-Dose Vial, Rx only, Manufactured by: Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591; Marketed by: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY 10591), NDC 61755-008-01
Sold in
Nationwide
Made for
Adults (0 months and older)

Details

Units affected
21,353 vials
Illnesses reported
None reported
Manufactured in
777 Old Saw Mill River Rd, Tarrytown, NY, United States
Classification
Class II
Recall number
D-0767-2026

In the FDA's words

Description
Libtayo (cemiplimab-rwlc) Injection, 350 mg/7 mL (50 mg/mL), For Intravenous Infusion After Dilution, Single-Dose Vial, Rx only, Manufactured by: Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591; Marketed by: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY 10591), NDC 61755-008-01 Lack of Assurance of Sterility Lot: 8494000002, Exp 7/31/28 Distribution: USA Nationwide Affected quantity: 21,353 vials
Hazard
Lack of Assurance of Sterility

Related topics

SterilityDrugsSold nationwideMore from FDA Drug